Tocqueville Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Tocqueville Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,625	Closed	-$384K	–	845
2017 Q1	$384K	Sell	10,625 -950	-8%	-$41.9K	﹤0.01%	627
2016 Q4	$580K	Sell	11,575 -13,000	-53%	-$683K	0.01%	573
2016 Q3	$1.29M	Sell	24,575 -20,600	-46%	-$984K	0.02%	476
2016 Q2	$1.87M	Sell	45,175 -1,000	-2%	-$43.5K	0.02%	422
2016 Q1	$1.88M	Buy	46,175 +500	+1%	+$17.2K	0.02%	408
2015 Q4	$1.9M	Buy	45,675 +7,500	+20%	+$251K	0.03%	434
2015 Q3	$588K	Buy	38,175 +500	+1%	+$10.7K	0.01%	662
2015 Q2	$936K	Buy	37,675 +11,675	+45%	+$260K	0.01%	582
2015 Q1	$594K	Buy	26,000 +12,775	+97%	+$322K	0.01%	681
2014 Q4	$357K	Buy	13,225 +2,000	+18%	+$34.4K	﹤0.01%	774
2014 Q3	$132K	Sell	11,225 -26,800	-70%	-$338K	﹤0.01%	842
2014 Q2	$591K	Sell	38,025 -2,000	-5%	-$28.7K	0.01%	682
2014 Q1	$787K	Buy	+40,025	New	+$680K	0.01%	493

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Tocqueville Asset Management's FPRX Position: Q2 2017 in Review

Tocqueville Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 10,625 shares — an estimated $384K sold.

Tocqueville Asset Management first reported a position in FPRX in Q1 2014 and held it in 13 quarters. The position peaked at $1.9M in Q4 2015. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

Tocqueville Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Tocqueville Asset Management sold 10,625 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $384K.
Tocqueville Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
Tocqueville Asset Management's Five Prime Therapeutics, Inc. position peaked at $1.9M in Q4 2015.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Tocqueville Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.